Afrezza pediatric approval and new data put MannKind back on investors’ radar

MannKind (MNKD) is drawing fresh attention after US regulators cleared Afrezza for children and adolescents aged 6 and older, alongside new Afrezza and FUROSCIX data showcased at the American Diabetes Association’s 2026 Scientific Sessions.

Those Afrezza and pipeline updates have arrived alongside a sharp positive swing in MannKind’s 30 day and 90 day share price returns of 18.45% and 32.13%. However, the year to date share price return is still down 34.64% and the 1 year total shareholder return is slightly negative at 1.35%, so recent momentum is picking up from a weaker base.

If you are looking beyond MannKind for other opportunities in healthcare technology, this is a good moment to scan 40 healthcare AI stocks.

With MannKind sharing new data, a larger Afrezza label and a stock that has rebounded in recent months but is still down year to date, should you see value that others are missing, or has the market already priced in future growth?

Most Popular Narrative: 48.9% Undervalued

MannKind's most followed valuation story puts fair value at $7.17 per share compared with the last close of $3.66, a wide gap that comes from detailed earnings and cash flow assumptions.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are set to accelerate market penetration amid a rising global diabetes burden and an aging population, directly supporting revenue and earnings growth.

Multiple late-stage pipeline programs (inhaled clofazimine for NTM and nintedanib DPI for IPF) are progressing toward key regulatory and clinical milestones, benefiting from expedited pathways and growing unmet need in chronic respiratory diseases, with the potential to significantly diversify and expand future revenues.

The narrative leans on faster earnings growth than revenues, a higher long run profit margin, and a rich future earnings multiple to bridge today’s price to that fair value. Curious which assumptions matter most and how they stack across Afrezza, Tyvaso DPI royalties and the inhaled pipeline into 2029.

Result: Fair Value of $7.17 (UNDERVALUED)

However, this hinges on Afrezza gaining wider adoption and Tyvaso DPI royalties holding up if United Therapeutics progresses a competing soft mist inhaler device.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of fresh data, sentiment shifts and valuation debate has your attention, consider acting promptly. Review the details yourself and weigh both sides of the story by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If MannKind has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot other stocks that could fit your plan.

• Zero in on companies that trade below their estimated worth by checking the 44 high quality undervalued stocks before others catch on.
• Prioritize stability and sleep easier at night by searching for companies in the 71 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with solid fundamentals using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.